Johnson & Johnson (JNJ)
Johnson & Johnson - Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies drivingSjögrens disease
Johnson & Johnson - Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies drivingSjögrens disease
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak signals • Minimal impact expected **Sentiment:** Neutral (50%) **Content type:** General